Lancet Gastroenterology & Hepatology

Papers
(The H4-Index of Lancet Gastroenterology & Hepatology is 74. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Aldafermin in non-alcoholic steatohepatitis: a cautionary tale for trial design1590
Research in Brief557
EASL Congress 2024515
GORD: pain, PPIs, and preciseness454
Viral hepatitis: time for action447
Research in Brief447
Correction to Lancet Gastroenterol Hepatol 2025; 10: 418–30421
Nationwide practice change after early termination of a randomised trial of laparoscopic pancreatoduodenectomy337
Immune checkpoint inhibitors in colorectal cancer: dream and reality336
The role of ERAS in robotic pancreaticoduodenectomy – Authors' reply304
Treatment withdrawal in Crohn's disease: slowly becoming clearer282
Correction to Lancet Gastroenterol Hepatol 2017; 2: 103–11264
Lucky: Learning to Live Again244
Neoadjuvant immunotherapy for resectable hepatocellular carcinoma233
Trends in alcohol-specific deaths in the UK and industry responses222
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept t220
AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled220
A procalcitonin-based algorithm to guide antibiotic use in patients with acute pancreatitis (PROCAP): a single-centre, patient-blinded, randomised controlled trial218
International expert guidance for defining and monitoring small bowel strictures in Crohn's disease on intestinal ultrasound: a consensus statement214
Deep neural network for video colonoscopy of ulcerative colitis: a cross-sectional study208
Closing the gender gap in gastroenterology leadership: the need for effective and comprehensive allyship203
Upfront endoscopic necrosectomy or step-up endoscopic approach for infected necrotising pancreatitis (DESTIN): a single-blinded, multicentre, randomised trial194
Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study187
Management of pouch neoplasia: consensus guidelines from the International Ileal Pouch Consortium183
Global multi-stakeholder endorsement of the MAFLD definition171
Effectiveness and predictors of response to somatostatin analogues in patients with gastrointestinal angiodysplasias: a systematic review and individual patient data meta-analysis168
ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension166
Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives165
Systemic therapy with or without local intervention for oligometastatic oesophageal squamous cell carcinoma (ESO-Shanghai 13): an open-label, randomised, phase 2 trial161
Rare cause of dysphagia in a young woman154
Water and sanitation for all154
ACG 2024145
Long-term VEDOKIDS results: implications for practice and research137
Endoscopist deskilling: an unintended consequence of AI-assisted colonoscopy?136
Addressing inequities in access to care among Indigenous peoples with chronic hepatitis C in Alberta, Canada135
Availability of point-of-care HBV tests in resource-limited settings132
Haematopoietic stem-cell transplantation for patients with Crohn's disease: primum non nocere131
The pitfalls and promises of scoping reviews in gastroenterology literature – Authors’ reply129
Management of portal vein thrombosis in cirrhosis127
The potential of ctDNA in locoregional therapies for colorectal cancer126
Idiopathic gastroparesis consensus misses the patient's voice125
Local and systemic therapy in liver cancer: the quest for synergy124
All roads lead to the gut–brain microbiome network123
Research in Brief121
Uptick of food allergies in recent years—real or epiphenomenon?116
Has the time come for a systematic top-down approach in Crohn's disease?113
Combined tumour-infiltrating lymphocytes and microsatellite instability status as prognostic markers in colorectal cancer – Authors' reply110
Phosphatidylethanol and self-reported alcohol intake to subclassify individuals at risk of steatotic liver disease: an analysis of data from a prospective cohort study108
Correction to Lancet Gastroenterol Hepatol 2022; 7: 627–47108
The present and future of gastroenterology and hepatology: an international SWOT analysis (the GASTROSWOT project)105
Resmetirom for NASH: balancing promise and prudence104
Addressing the rise of early-onset colorectal cancer103
COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study101
U-ACTIVATE long-term efficacy and safety outcomes for upadacitinib in ulcerative colitis100
Sex and gender in inflammatory bowel disease outcomes and research100
Bringing organ preservation closer for selected patients with rectal cancer100
Prevalence of hepatitis C virus seropositivity and active infection in a Rohingya refugee population in Cox's Bazar camps, Bangladesh: a cross-sectional study98
Transjugular intrahepatic portosystemic shunt with or without gastro-oesophageal variceal embolisation for the prevention of variceal rebleeding: a randomised controlled trial98
Hypovolaemic phlebotomy for hepatic resection97
Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review97
Unifying the approach to tackling inequalities in liver health: learning from working with underserved populations94
Closing the gender gap: building a successful career and leadership in research as a female gastroenterologist92
Managing inflammatory bowel disease: what to do when the best is unaffordable?89
Lifting the minority tax in gastroenterology and hepatology87
Research in Brief85
The Year My Life Went Down the Toilet84
Britta Siegmund: answering the big questions in IBD83
Research in Brief80
Dangerous Medicine80
Management of malignant bowel obstruction – Authors' reply80
An unusual complication after a variceal glue injection80
A women-focused matrix mentorship programme in gastroenterology79
The growth of faecal microbiota transplantation in the UK: time for a registry?78
Another arrow in the NASH quiver?77
Early antiviral therapy in adults with moderate to highly viraemic chronic hepatitis B74
0.2050359249115